Clinical Trial

Pharmacogenetics of Leflunomide in the Management of Rheumatoid Arthritis

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 5, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
1. Patients taking leflunomide as the only disease-modifying anti-rheumatic drug (DMARD) will be recruited after consent. 2. Blood sample for DNA extraction will be taken The patient will be followed up till two visits 3 months apart, and efficacy and toxicity will be checked using DAS28, ultrasonography, and blood tests for ESR, CRP, anti-CCP, liver function tests, etc. The data form for toxicity will be filled. 3. DNA will be extracted in the laboratory, and SNP will be identified. 4. The efficacy and toxicity data will be studied against the SNPs found 5. An algorithm will be constructed for Pakistani RA patients taking leflunomide.
Trial Details
NCT Number NCT07388407
Lead Sponsor Foundation University Islamabad
Collaborators: Shifa Tameer-e-Millat University
Conditions Rhematoid Arthritis
Enrollment 110 participants
Start Date 2024-09-01
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-05